FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints – Ortho Spine News

FibroBiologics (FBLG) presented preclinical data at the North American Spine Society Annual Meeting, showing statistically significant improvements in disc height for all fibroblast-treated groups in a 12-week rabbit model. The FSdC spheroid group showed the highest percent disc height index at 80.7% compared to 71.8% in controls. The company develops treatments using fibroblast cells and holds over 270 patents.

FibroBiologics (FBLG) presented preclinical data at the NASS 2026 Annual Meeting, showing its FSdC spheroids preserved disc height better than other fibroblast-based approaches in a 12-week rabbit model of degenerative disc disease. Key findings include significant improvements in disc height and matrix remodeling, with FSdC spheroids showing the highest %DHI of 80.7% compared to 71.8% in controls.

FibroBiologics (FBLG) received a new U.S. patent (No. 12,716,055) for treating degenerative disc disease using fibroblast conditioned media. The patent covers methods to stimulate fibroblasts with opioid receptor antagonists and TLR agonists to boost regenerative growth factors. The company claims this expands its IP portfolio in disc degeneration, one of its core clinical pathways, with over 270 issued and pending patents. FibroBiologics aims to develop non-invasive treatments for disc regenera

FibroBiologics (Nasdaq: FBLG) reported Q2 2026 results and said it dosed the first patients in its Phase 1/2 trial of CYWC628 for diabetic foot ulcers. It completed cGMP manufacturing of three CYWC628 batches. The company raised $9.0 million via private placement and $3.0 million in a public offering. Q2 net loss was about $4.1 million, with cash of about $3.5 million at June 30, 2026.

FibroBiologics (NASDAQ:FBLG) said it has enrolled and dosed the first patients in its Phase 1/2 trial of CYWC628 for diabetic foot ulcers. The multicenter randomized study in Australia will enroll up to 120 patients to test safety, tolerability, and efficacy versus standard of care, with an interim analysis after 6 weeks. The company previously guided interim results for Q3 2026.

AbCellera Biologics (ABCL) plans to advance its hot-flash drug, ABCL635, into Phase 3 trials after promising Phase 2 results. The company is modeling dosing and engaging in regulatory discussions with the FDA. ABCL635 showed sleep-score results comparable to Bayer's LYNKUET, according to the company. AbCellera is also developing other candidates, including ABCL992, a longer-acting version of ABCL635.